Patents by Inventor Velpandi Ayyavoo

Velpandi Ayyavoo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Attenuated vif DNA immunization cassettes for genetic vaccines
    Patent number: 8183352
    Abstract: The present invention is directed to nucleic acid molecules encoding attenuated, non-functional virion infectivity factor (vif) proteins. The nucleic acid molecules of the invention are inserted into recombinant expression vectors and administered to mammals in order to induce a cellular and humoral immune response to the encoded protein product.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: May 22, 2012
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Velpandi Ayyavoo, Thanadavarayan Nagashunmugam, David B. Weiner
  • Nucleic acid expression cassette encoding an HIV polyprotein comprising the ancillary gene products Vif, Vpu, and Nef
    Patent number: 7488484
    Abstract: Improved vaccines and methods of using the same are disclosed. Immunosuppressive compositions for treating individuals who have autoimmune diseases or transplants and methods of using the same are disclosed.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: February 10, 2009
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, Velpandi Ayyavoo
  • Attenuated vif DNA immunization cassettes for genetic vaccines
    Publication number: 20070106062
    Abstract: The present invention is directed to nucleic acid molecules encoding attenuated, non-functional virion infectivity factor (vif) proteins. The nucleic acid molecules of the invention are inserted into recombinant expression vectors and administered to mammals in order to induce a cellular and humoral immune response to the encoded protein product.
    Type: Application
    Filed: December 15, 2006
    Publication date: May 10, 2007
    Inventors: Velpandi Ayyavoo, Thanadavarayan Nagashunmugam, David Weiner
  • Attenuated DNA immunization cassettes for genetic vaccines
    Patent number: 7151172
    Abstract: The present invention is directed to nucleic acid molecules encoding attenuated, non-functional virion infectivity factor (vif) proteins. The nucleic acid molecules of the invention are inserted into recombinant expression vectors and administered to mammals in order to induce a cellular and humoral immune response to the encoded protein product.
    Type: Grant
    Filed: September 18, 1998
    Date of Patent: December 19, 2006
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Velpandi Ayyavoo, Thanadavarayan Nagashunmugam, David B. Weiner
  • Functional fragments of HIV-1 VPR protein and methods of using the same
    Publication number: 20060088551
    Abstract: Conjugated compositions comprising a fragment of HIV-1 Vpr or a non-HIV-1 Vpr protein conjugated to a therapeutic compounds and methods of using the same to deliver therapeutic compounds to a cell's nucleus or for the preparation of drug delivery particles are disclosed. Functional fragments of HIV-1 Vpr and functional non-HIV-1 Vpr proteins, and pharmaceutical compositions comprising the same are disclosed. Methods of inhibiting cell proliferation and methods of treating an individual who has a hyperproliferative disease are disclosed. Methods of identifying compounds that inhibit Vpr protein binding to the p6 domain of p55 or to p6 protein and kits for performing such methods are disclosed.
    Type: Application
    Filed: September 29, 2004
    Publication date: April 27, 2006
    Inventors: Sundarasamy Mahalingam, Velpandi Ayyavoo, Mamata Patel, Thomas Kieber-Emmons, David Weiner
  • Cellular receptor for HIV-1 Vpr essential for G2/M phase transition of the cell cycle
    Patent number: 6949337
    Abstract: The present invention provides methods of identifying anti-HIV compound by contacting human Vpr Interacting Protein (hVIP), or a fragment thereof known to interact with Vpr, with Vpr, or a fragment thereof known to interact with hVIP in the presence of a test compound, and comparing the affinity of the hVIP or fragment thereof to the Vpr or fragment thereof in the presence of the test compound with the affinity of the hVIP or fragment thereof to the Vpr or fragment thereof in the absence of the test compound. The present invention also provides transgenic non-human mammals comprising a recombinant expression vector that comprises a nucleic acid sequence that encodes hVIP.
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: September 27, 2005
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, Velpandi Ayyavoo, Sundarasamy Mahalingam, Mamata Patel
  • Functional fragments of HIV-1 Vpr protein and methods of using the same
    Patent number: 6818627
    Abstract: Conjugated compositions comprising a fragment of HIV-1 Vpr or a non-HIV-1 Vpr protein conjugated to a therapeutic compound and methods of using the same to deliver therapeutic compounds to a cell's nucleus or for the preparation of drug delivery particles are disclosed. Functional fragments of HIV-1 Vpr and functional non-HIV-1 Vpr proteins, and pharmaceutical compositions comprising the same are disclosed. Methods of inhibiting cell proliferation and methods of treating an individual who has a hyperproliferative disease are disclosed. Methods of identifying compounds that inhibit Vpr protein binding to the p6 domain of p55 or to p6 protein and kits for performing such methods are disclosed.
    Type: Grant
    Filed: October 5, 2000
    Date of Patent: November 16, 2004
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Sundarasamy Mahalingam, Velpandi Ayyavoo, Mamata Patel, Thomas Kieber-Emmons, David B. Weiner
  • Compositions and methods for the abrogation of cellular proliferation utilizing the human immunodeficiency virus VPR protein
    Patent number: 6667157
    Abstract: Method of inhibiting proliferation of cells using vpr protein or nucleotide sequences that encode vpr are disclosed. Method of preventing lymphocyte activation using vpr protein or nucleotide sequences that encode vpr are disclosed. Methods of treating an individual diagnosed with or suspected of suffering from autoimmune disease, diseases characterized by proliferating cells and graft versus host disease by administering vpr protein or a functional fragment thereof, or a nucleic acid molecule that comprises a nucleotide sequence that encodes vpr protein or a functional fragment thereof are disclosed. Conjugated compositions for delivery of active agents to the nucleus of cells are disclosed.
    Type: Grant
    Filed: June 24, 1997
    Date of Patent: December 23, 2003
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, David N. Levy, Yosef Refaeli, William V. Williams, Velpandi Ayyavoo
  • Cellular receptor for HIV-1 Vpr essential for G2/M phase transition of the cell cycle
    Publication number: 20030143735
    Abstract: The present invention provides methods of identifying an anti-HIV compound by contacting human Vpr Interacting Protein (hVIP), or a fragment thereof known to interact with Vpr, with Vpr, or a fragment thereof known to interact with hVIP in the presence of a test compound, and comparing the affinity of the hVIP or fragment thereof to the Vpr or fragment thereof in the presence of the test compound with the affinity of the hVIP or fragment thereof to the Vpr or fragment thereof in the absence of the test compound. The present invention also provides transgenic non-human mammals comprising a recombinant expression vector that comprises a nucleic acid sequence that encodes hVIP.
    Type: Application
    Filed: February 27, 2003
    Publication date: July 31, 2003
    Inventors: David B. Weiner, Velpandi Ayyavoo, Sundarasamy Mahalingam, Mamata Patel
  • Cellular receptor for HIV-1 Vpr essential for G2/M phase transition of the cell cycle
    Patent number: 6448078
    Abstract: The present invention is directed to substantially pure Human Vpr Interacting Protein (hVIP), and fragments thereof.
    Type: Grant
    Filed: October 17, 2000
    Date of Patent: September 10, 2002
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, Velpandi Ayyavoo, Sundarasamy Mahalingam, Mamata Patel
  • Cellular receptor for HIV-1 Vpr essential for G2/M phase
    Patent number: 6172201
    Abstract: The present invention is directed to substantially pure human Vpr Interacting Protein (hVIP), and fragments thereof.
    Type: Grant
    Filed: October 13, 1999
    Date of Patent: January 9, 2001
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, Velpandi Ayyavoo, Sundarasamy Mahalingam, Mamata Patel
  • Nucleotide sequences encoding vpr receptor protein
    Patent number: 6087486
    Abstract: DNA molecules which encode rip-1 protein sequences are disclosed. Expression vectors and host cells which include the DNA molecules are disclosed.
    Type: Grant
    Filed: January 28, 1998
    Date of Patent: July 11, 2000
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, Velpandi Ayyavoo, Sundarasama Mahalingham, William V. Williams
  • Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle
    Patent number: 6060587
    Abstract: The present invention is directed to substantially pure human Vpr Interacting Protein (hVIP), and fragments thereof.
    Type: Grant
    Filed: October 10, 1997
    Date of Patent: May 9, 2000
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, Velpandi Ayyavoo, Sundarasamy Mahalingam, Mamata Patel